Growth Hormone Secretagogues

CJC-1295 (no DAC)

Also known as CJC-1295 without DAC · Mod GRF 1-29 · Modified GRF 1-29 · CJC-1295 DAC-free

PreliminarySubcutaneous injectionNot FDA-approved for any indication. Was placed on FDA's interim Category 2 list of bulk drug substances in compounding, then removed from that list in September 2024; subsequent Pharmacy Compounding Advisory Committee review did not establish a 503A compounding pathway, leaving its compounding status unresolved. Prohibited in sport (WADA, S2). Research/compounded use only.

CJC-1295 without DAC, often labeled Modified GRF 1-29, is a GHRH analog carrying amino-acid substitutions intended to resist enzymatic breakdown while retaining a comparatively short duration of action. Like native GHRH it acts on pituitary GHRH receptors to trigger a discrete, transient pulse of growth hormone. In research it has been studied alongside ghrelin-receptor agonists such as ipamorelin, a pairing investigated for its effect on each growth-hormone pulse. It is not an approved medicine and is encountered in research and compounded settings only.

Studied / used for

Studied for stimulation of pulsatile endogenous growth hormone release
Used in research protocols paired with ghrelin-receptor agonists
Explored for effects on body composition and IGF-1 levels

Commonly reported side effects

Injection-site reactions
Facial flushing or warmth
Headache
Fluid retention
Transient drop in blood pressure or lightheadedness

Preliminary. Mostly early or animal studies. This reflects the strength of the research base, not effectiveness or a recommendation.

Not medical advice.

This is an educational reference. Peptalk does not recommend, prescribe, endorse, or rate any compound, and provides no dosing information. Do not start, stop, or change any peptide, hormone, supplement, or therapy based on this page. All clinical decisions must be made with your licensed healthcare provider.

← Back to all compounds